| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Cytarabine | FIMM | pan-cancer | AAC | 0.035 | 0.8 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | -0.0073 | 0.8 |
| mRNA | BCL-LZH-4 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Nilotinib | GDSC1000 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Nilotinib | CTRPv2 | pan-cancer | AAC | -0.0074 | 0.8 |
| mRNA | BRD-K66532283 | CTRPv2 | pan-cancer | AAC | -0.0067 | 0.8 |
| mRNA | NVP-BEZ235 | GDSC1000 | pan-cancer | AAC | -0.0068 | 0.8 |
| mRNA | EX-527 | CTRPv2 | pan-cancer | AAC | 0.0076 | 0.8 |
| mRNA | QS11 | CTRPv2 | pan-cancer | AAC | -0.014 | 0.8 |